Engitix Pharma (03696) and Novartis have reached a long-term collaboration worth $888 million for the development of anti-tumor drugs.

English Silicone Intelligence (03696) announced that the group has entered into a long-term research and development partnership with a global independent pharmaceutical company managed by a foundation, Schweyad. The collaboration is valued at up to $888 million and will make full use of the group's self-developed artificial intelligence platform Pharma.AI, focusing on challenging targets in the field of anti-tumor, identifying and developing new therapeutic drugs. Under the agreement, the group will be eligible to receive up to $32 million in upfront payments and near-term research milestone payments, and will lead the use of artificial intelligence technology platform to discover and develop potential candidate drugs that meet established standards, with Schweyad sharing in the research and development costs and leading the subsequent clinical validation and commercialization process. Christophe Thurieau, Executive Director of Schweyad Research Institute, commented: "This partnership demonstrates Schweyad's commitment to using cutting-edge technology to address unmet medical needs and ultimately benefit patients, and it also reflects our confidence in Silicone Intelligence's self-developed and validated artificial intelligence platform." Dr. Alex Zhavoronkov, Founder, CEO, and Chief Business Officer of Silicone Intelligence, said: "I am very excited about this collaboration, which demonstrates once again the recognition of our artificial intelligence drug development capability and strength. As we further integrate generative artificial intelligence into various stages of the drug development value chain, I believe the future of pharmaceutical superintelligence is just around the corner, where AI intelligence can truly make decisions and design experiments to drive a faster, smarter, and safer virtuous cycle of drug development."